What You Need To Know
- JSUMC is now enrolling patients with agitation-related to Alzheimer’s disease in a double-blinded clinical trial called the ASPECT study.
- The purpose of the study is to find out whether an investigational medication called AVP-786 is safe and effective in managing agitation in patients with Alzheimer’s disease when compared to placebo.
To be eligible for the ASPECT study, patients must:
- Be between the ages of 50 and 90;
- Have a diagnosis of probable Alzheimer’s disease;
- Have moderate-to-severe agitation that interferes with daily life;
- Have a caregiver who spends a minimum of two hours per day, four days per week, with them and is willing to comply with all study procedures, including administering the drug and attending study visits.
Patients and caregivers who are eligible to participate will be asked to attend 10 study visits over a period of 20 weeks, including a four-week screening period, a 12-week treatment period, and a follow-up visit about 30 days after the last treatment visit. Each study visit will last about 2-3 hours.
To learn more or make a referral
Contact Robert G. Stern, M.D., Section Chief, Geriatric Psychiatry at robert.stern@hmhn.org.